Avalo Therapeutics Director Kevin Lind Receives 20,100 Stock Options

This Form 4 filing reports that Kevin Robert Lind, a director of Avalo Therapeutics, Inc. (AVTX), was granted 20,100 stock options on June 2, 2026. The options have an exercise price of $13.96 per share and expire on June 2, 2036. The grant vests 100% on the first anniversary of the grant date, contingent on Lind's continued service as a director through that date. Following this transaction, Lind holds 20,100 stock options in the company. The filing represents a standard equity compensation award to a non-executive director, which is common practice for board members of public companies to align their interests with shareholders.